Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Prepaid Assets (2016 - 2025)

UroGen Pharma (URGN) has disclosed Prepaid Assets for 10 consecutive years, with $14.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Prepaid Assets rose 65.88% year-over-year to $14.7 million, compared with a TTM value of $14.7 million through Dec 2025, up 65.88%, and an annual FY2025 reading of $14.7 million, up 65.88% over the prior year.
  • Prepaid Assets was $14.7 million for Q4 2025 at UroGen Pharma, up from $12.1 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $16.0 million in Q3 2023 and bottomed at $5.3 million in Q2 2021.
  • Average Prepaid Assets over 5 years is $10.8 million, with a median of $10.8 million recorded in 2022.
  • The sharpest move saw Prepaid Assets skyrocketed 306.96% in 2021, then decreased 13.97% in 2024.
  • Year by year, Prepaid Assets stood at $7.5 million in 2021, then surged by 48.49% to $11.1 million in 2022, then decreased by 7.39% to $10.3 million in 2023, then fell by 13.97% to $8.8 million in 2024, then skyrocketed by 65.88% to $14.7 million in 2025.
  • Business Quant data shows Prepaid Assets for URGN at $14.7 million in Q4 2025, $12.1 million in Q3 2025, and $12.1 million in Q2 2025.